Uses of OpeSpira 1.5

This is an automatically translated article.

OpeSpira 1.5 MIU is an antibiotic that can be used to treat certain infections. So what are the uses of OpeSpira 1.5 MIU? Find out what is shared in the following article.

1. What is OpeSpira 1.5 MIU?

OpeSpira contains the main ingredient OpeSpira 1.5 MIU. The drug is made in the form of film-coated tablets by OPV pharmaceutical company in Vietnam.

2. Indications for the use of OpeSpira 1.5 MIU

OpeSpira 1.5 MIU drug should be used according to the prescription and guidance of a specialist. Generally, antibiotic OpeSpira 1.5 MIU is indicated for the treatment of infections caused by susceptible bacteria such as:
Respiratory tract infections: Tonsillitis, pharyngitis, sinusitis, acute otitis media, pneumonia and bronchitis manage . People with skin infections. People with genital infections. Prophylaxis of congenital toxoplasmosis in pregnant women and immunocompromised patients. Prophylaxis of meningococcal meningitis. Prophylaxis of recurrence of acute rheumatic fever in patients allergic to penicillin antibiotics. Prophylaxis of recurrence of rheumatic fever in the setting of penicillin allergy.

3. How to use and dose OpeSpira 1.5 MIU

3.1 How to take antibiotics OpeSpira 1.5 MIU
Patients take OpeSpira before meals, orally, at least 2 hours or 3 hours after meals. To maximize the effectiveness of OpeSpira treatment, you should adhere to the dose prescribed by your doctor, do not suddenly increase, decrease or stop using the drug. 3.2 Dosage of OpeSpira 1.5 MIU Treatment of bacterial infections in adults: 3,000,000-6,000,000 IU, orally twice a day. Or 1,500,000 - 3,000,000 IU, 3 times a day. Severe infections use a dose of 6,000,000 - 7,500,000 IU, orally twice a day. Treatment of bacterial infections in children from 20kg and over: 1,500,000 IU/10kg. Drink 2-3 times a day. Prophylactic treatment of meningococcal meningitis: Children: 1,500,000 IU/10kg body weight, 2 times a day x 5 days. Prophylaxis of congenital Toxoplasma infection in pregnant women: 9,000,000 IU/day, orally 3-4 times/day x 3 weeks.

4. Contraindications to the use of OpeSpira 1.5 MIU

OpeSpira 1.5 MIU is contraindicated for people who are sensitive to Spiramycin or macrolide antibiotics such as: Erythromycin, Oleandomycin, Roxithromycin, Clarithromycin, Dirithromycin, Azithromycin, Josamycin,... Or any ingredient of the drug.

5. Possible side effects when taking OpeSpira 1.5 MIU

During the use of OpeSpira 1.5 MIU, patients may experience some side effects as follows:
Common: Vomiting, nausea, diarrhea, indigestion, fatigue, nosebleeds, sweating , chest tightness, acute colitis, rash and urticaria. Uncommon: Temporary paresthesia, dysesthesia, grogginess, pain, muscle and joint stiffness and burning sensation. Rare: Anaphylactic reactions, superinfection due to long-term treatment with Spiramycin and prolongation of the QT interval. Note: The side effects of the drug OpeSpira 1.5 MIU mentioned above may be incomplete because each patient has a different body. Patients should inform their doctor about the side effects they are experiencing when using the antibiotic OpeSpira 1.5 MIU for appropriate management.

6. OpeSpira 1.5 MIU drug interactions

OpeSpira 1.5 MIU may cause an interaction reaction if used concomitantly with:
Oral contraceptives. If combined, it will lose the effect of preventing pregnancy. Levodopa drug. To avoid interactions, before being prescribed OpeSpira 1.5 MIU, patients should inform their doctors about all the drugs they are taking, including supplements. The doctor will base it on that to prescribe the appropriate OpeSpira 1.5 MIU.

7. Treatment of OpeSpira 1.5 MIU overdose

The toxic dose of OpeSpira 1.5 MIU is currently unknown. However, when using OpeSpira 1.5 MIU in high doses, it can cause gastrointestinal disorders such as nausea, vomiting and diarrhea. The heart may experience a prolongation of the QT interval, which will subside when the drug is stopped.
Guidelines for the management of OpeSpira 1.5 MIU overdose: In case of overdose, an electrocardiogram can be performed to measure the QT interval. There is currently no antidote for OpeSpira 1.5 MIU, so only symptomatic treatment is continued for patients.

8. Notes and cautions when using OpeSpira 1.5 MIU

People with liver dysfunction should be careful when using OpeSpira because the drug can cause liver toxicity. People with heart disease and arrhythmia should consult their doctor before using OpeSpira 1.5 MIU. When starting treatment, if you experience a generalized rash with fever, you should stop taking the drug immediately and notify the doctor. Women who are exclusively breastfeeding should stop breastfeeding while taking OpeSpira. Pregnant women: OpeSpira 1.5 MIU crosses the placenta, but the concentration of the drug in the fetal blood is lower than in the mother's blood. Therefore, the drug can still be used for this subject. However, consult your doctor before use. The above article has provided information on what OpeSpira 1.5 MIU is used for, dosage and notes when using the drug. To ensure safety for health and maximize the effectiveness of treatment, patients should use OpeSpira 1.5 MIU exactly as directed by their doctor. Store OpeSpira in a cool, dry place at a temperature not exceeding 30 degrees Celsius and out of the reach of small children.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.